Neuberger Berman Group LLC Boosts Stake in ZimVie Inc. $ZIMV

Key Points

• Neuberger Berman Group LLC increased its stake in ZimVie Inc. by 1.7%, owning approximately 4.79% of the company with 1,332,890 shares valued at $14.4 million.
• ZimVie reported quarterly earnings of $0.26 per share, surpassing analyst expectations, while its revenue reached $116.66 million against a consensus estimate of $112.60 million.
• Recent analyst ratings for ZimVie include a downgrade from UBS Group, while Barclays upgraded the stock from "underweight" to "equal weight" with a target price increase to $19.00.

Neuberger Berman Group LLC lifted its stake in ZimVie Inc. (NASDAQ:ZIMV - Free Report) by 1.7% during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,332,890 shares of the company's stock after acquiring an additional 22,075 shares during the period. Neuberger Berman Group LLC owned 4.79% of ZimVie worth $14,435,000 at the end of the most recent reporting period.

Several other institutional investors also recently added to or reduced their stakes in the business. Wealthquest Corp acquired a new stake in shares of ZimVie during the 1st quarter worth approximately $182,000. Wealth Enhancement Advisory Services LLC raised its position in shares of ZimVie by 5.8% during the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 15,127 shares of the company's stock worth $211,000 after acquiring an additional 836 shares during the last quarter. Wells Fargo & Company MN increased its holdings in ZimVie by 17.8% in the fourth quarter. Wells Fargo & Company MN now owns 17,037 shares of the company's stock valued at $238,000 after purchasing an additional 2,569 shares during the last quarter. Deutsche Bank AG increased its holdings in ZimVie by 61.7% in the fourth quarter. Deutsche Bank AG now owns 23,796 shares of the company's stock valued at $332,000 after purchasing an additional 9,084 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in ZimVie by 8.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 24,571 shares of the company's stock valued at $343,000 after acquiring an additional 1,852 shares during the period. 95.63% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently commented on ZIMV shares. Wall Street Zen cut ZimVie from a "strong-buy" rating to a "buy" rating in a research report on Friday, July 18th. Barclays raised ZimVie from an "underweight" rating to an "equal weight" rating and raised their price objective for the company from $9.00 to $19.00 in a research report on Tuesday, July 22nd. UBS Group cut their price objective on ZimVie from $16.00 to $10.00 and set a "neutral" rating for the company in a research report on Thursday, May 15th. Finally, B. Riley lowered ZimVie from a "buy" rating to a "neutral" rating and set a $19.00 price objective on the stock. in a research note on Thursday, July 31st. Four research analysts have rated the stock with a Hold rating, According to MarketBeat, the stock has a consensus rating of "Hold" and an average price target of $17.75.

ZimVie Price Performance

Shares of ZIMV traded up $0.0150 during trading hours on Tuesday, reaching $18.9650. 207,719 shares of the stock traded hands, compared to its average volume of 285,350. The company has a current ratio of 2.37, a quick ratio of 1.60 and a debt-to-equity ratio of 0.56. ZimVie Inc. has a 52-week low of $8.15 and a 52-week high of $18.98. The company's 50-day moving average price is $13.23 and its two-hundred day moving average price is $11.59. The company has a market cap of $534.81 million, a P/E ratio of -27.09 and a beta of 2.20.

ZimVie (NASDAQ:ZIMV - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.26 EPS for the quarter, topping the consensus estimate of $0.21 by $0.05. The business had revenue of $116.66 million for the quarter, compared to analysts' expectations of $112.60 million. ZimVie had a negative net margin of 4.39% and a positive return on equity of 6.37%. On average, analysts anticipate that ZimVie Inc. will post 0.6 earnings per share for the current year.

ZimVie Company Profile

ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.